Posted by Michael Wonder on 17 Sep 2025
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
16 September 2025 - Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Durvalumab (Imfinzi, AstraZeneca) is recommended in final draft guidance for adults with limited-stage small cell lung cancer.
